Reading the claims

Blue Light And What The Evidence Actually Shows

Macular pigment is yellow, and yellow absorbs blue. That much is optics and nobody disputes it. What happens next, when a supplement label turns that fact into a promise about screens, is where the evidence and the marketing separate, and the best review in the area says three different things that keep getting collapsed into one.

Written by Visivra Team at Myvisivra · Reviewed by Dr. Rishi Singh, MD · Updated November 4, 2026 · Reading the claims

The part that is settled

Start with what nobody argues about, because it is the foundation everything else is built on and it is genuinely solid.

The macula carries a layer of yellow pigment made of lutein and zeaxanthin, sitting in front of the photoreceptors. Yellow pigment absorbs short-wavelength light. Blue is the short wavelength end of the visible spectrum and it is the end that scatters most inside the eye, which is why a hazy sky is blue and why glare has the quality it does.

So the layer acts as an internal filter and an internal glare screen at the same time, and it is measurable. Macular pigment optical density is a real number an instrument reads, and trials that supplement carotenoids report it going up.

Where the reasoning starts to stretch

From 'the pigment absorbs blue light' to 'therefore a capsule protects you from screens' is several steps, and each one needs its own evidence. Does the layer thicken enough to matter? Does a thicker layer change anything a person notices? Is screen blue light a meaningful exposure in the first place? Those are three separate empirical questions.

What the best review actually found

The strongest evidence in this area is the 2023 Cochrane review of blue-light filtering spectacle lenses. It is about lenses rather than capsules, and it is quoted here because it is the nearest well-conducted evidence to the question rather than because it is a substitute for a supplement trial.

Four separate conclusions from one review, routinely collapsed into a single sentence in both directions. The third is the one most often misquoted.

Four conclusions, and they are not the same conclusion. Probably little or no short-term effect on acuity is a finding. Indeterminate on sleep is an admission that the trials disagree. And no randomised evidence on macular health is a statement about the absence of research rather than about the presence of an effect.

The sentence that gets misquoted in both directions

The third row is the one worth being careful about, because it is misused by people selling things and by people debunking them.

The marketing misreading: ignoring the row entirely and implying that filtering blue light protects the macula. Nothing in that review supports the claim, and the honest word for research that has not been done is 'unknown'.

The debunking misreading: reporting the row as 'blue light does not affect macular health'. That is also not what it says. An absence of randomised evidence means the trial has not been run, which leaves the question open rather than closed.

Holding both of those at once is uncomfortable and it is the accurate position. The physics is real, the pigment is measurable, and whether any of it changes an outcome a person cares about has not been established by a randomised trial.

What the capsule evidence does say

Set the lens review aside and look at what the carotenoid trials themselves measured, because it is more interesting than the blue-light framing suggests.

CREST enriched macular pigment in people free of retinal disease and reported improved contrast sensitivity at twelve months. A separate trial examined contrast sensitivity and lateral inhibition with the same approach.

Contrast sensitivity is a better endpoint than anything in the blue-light conversation. It is the ability to distinguish a grey shape from a slightly different grey background, it is measurable on a chart, and it is what people are describing when they say things look washed out or that driving at dusk has become harder.

• The endpoint is contrast, not blue light. That is what the trials measured and what improved.
• The timescale is months. CREST measured at twelve.
• The population was healthy retinas, which is unusual in this field and makes it more relevant to an ordinary buyer than AREDS2 is.
• The amounts were stated. Ten milligrams of lutein and two of zeaxanthin is the reference pairing.

Screen fatigue is a different subject

Most people who buy an eye supplement for blue light are not worried about their macula at all. They are worried about how their eyes feel after eight hours at a display, and that is a different literature with different ingredients.

A trial in display-terminal workers gave 480 mg of bilberry extract a day for eight weeks to people whose job is a screen. A review of nutrition and digital eye strain covers the area as a whole, including how much of its outcome measurement is self-reported questionnaire rather than instrument.

That honesty about measurement matters. A questionnaire result is a real finding and it is a softer one than a chart, and a reader is entitled to know which kind of evidence a claim rests on.

How much blue light a screen actually emits

One number is worth having before any of this is worried about. Daylight delivers far more short-wavelength light than a display does, by a wide margin, and a person who spends an afternoon outdoors has received more blue light than a full working day at a monitor produces.

That does not make screen exposure irrelevant, because duration and viewing distance are different. It does mean a supplement sold specifically against screen blue light is addressing the smaller of two exposures, and any claim built on it should be read with that proportion in mind.

Six things that move the same symptoms

If the actual complaint is tired eyes at the end of a working day, the honest ranking of interventions is uncomfortable for anyone selling capsules.

Five free levers that act within a day, and one that takes months. The capsule is the last row for a reason.

Five of those six cost nothing and act within a day. The sixth costs money and takes months. That is not an argument against the capsule; it is an argument for doing the first five as well, and for being clear about which one is responsible if things improve.

How to read a blue-light claim on a label

Three questions separate a defensible blue-light claim from an indefensible one, and all three can be answered from the packaging.

1. Does it claim a mechanism or an outcome? 'Helps defend the eyes from blue light exposure' describes a filtering mechanism. 'Protects your eyes from screen damage' claims an outcome nobody has demonstrated.
2. Does it print the carotenoid amounts? The mechanism depends on building a pigment layer, and the layer depends on the dose. A blue-light claim on a label with no figures is resting on nothing checkable.
3. Does it mention anything else? A product that also tells a buyer about blink rate and screen breaks is being straight with them. One that positions a capsule as the whole answer is not.

The product this website sells prints 'help defend the eyes from blue light exposure' as one of four supports, which is a mechanism claim rather than an outcome claim. It does not print carotenoid amounts. Both of those facts are set out on the benefits page, where the fourth support gets a section of its own, and on the ingredients page.

References